<![CDATA[EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process]]>

EMA begins phased review of daraxonrasib for metastatic pancreatic cancer treatment

Phased review has started to accelerate assessment of medicine with potential to address high unmet medical need

EMA fast-tracks review of a medicine for metastatic pancreatic cancer

The human medicines committee (CHMP) at the European Medicines Agency (EMA) has started a phased review of data on daraxonrasib, a medicine

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM

Results of the earlier phase 1-2 study of 168 patients, published recently 🧪💊

First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know

Jun 1, 2026 - By Erin Post NEW — Additional Data on Daraxonrasib Released: “Significant Advances” for Pancreatic Cancer Treatment Daraxonras

New daily pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemothe

<![CDATA[Pembrolizumab Plus EV Regimens Receive FDA Approval for Muscle Invasive Bladder Cancer]]>